Owing to their particular mode of action, NAMPT inhibitors lend themselves to be used in combination regimes, enhancing the antitumor activity of targeted therapies such as histone deacetylase inhibitors [146] and tyrosine kinase inhibitors in leukemia [154] and WM [142], proteasome inhibitors in multiple myeloma [141], and mTOR inhibitors in pancreatic neuroendocrine tumors [160]. Here, NAMPT is linked to plasma cell myeloma.